Gwin E, Kerby G R, Ruth W E
Chest. 1977 Aug;72(2):148-53. doi: 10.1378/chest.72.2.148.
The control of asthma by therapy with cromolyn sodium was studied in 28 adults with late-onset asthma associated with hypersensitivity to aspirin and nasal polyps. Four-week periods of treatment with the drug or a placebo were compared in a double-blind crossover study. A subsequent eight-week open trial in 20 patients was compared to their period of receiving placebo. There was slight but significant improvement in the forced expiratory volume in one second (FEV1; P less than 0.05) and the mean forced expiratory flow during the middle half of the forced vital capacity (FEF25-75%; P less than 0.05) after four weeks of therapy with cromolyn sodium and in the FEV1 (P less than 0.05), the forced vital capacity (P less than 0.01), and FEF25-75% (P less than 0.01) after an additional eight weeks of therapy with cromolyn sodium. The improvement in pulmonary function was not associated with changes in the peak expiratory flow rate, the symptoms of asthma, the doses of additional medication, or the index of disability. The dosage of corticosteroids in 22 patients receiving long-term therapy with steroids was no different between the four-week periods of treatment with placebo or drug but was significantly lower (P less than 0.05) during the eight-week open trial. We conclude that administration of cromolyn sodium has a therapeutic effect in this group of asthmatic patients.
在28名患有与阿司匹林超敏反应及鼻息肉相关的迟发性哮喘的成年人中，研究了色甘酸钠治疗对哮喘的控制情况。在一项双盲交叉研究中，比较了该药物或安慰剂为期四周的治疗期。随后在20名患者中进行了为期八周的开放试验，并与他们接受安慰剂的时期进行了比较。在接受色甘酸钠治疗四周后，一秒用力呼气量（FEV1；P<0.05）和用力肺活量中间一半期间的平均用力呼气流量（FEF25-75%；P<0.05）有轻微但显著的改善，在额外接受色甘酸钠治疗八周后，FEV1（P<0.05）、用力肺活量（P<0.01）和FEF25-75%（P<0.01）也有改善。肺功能的改善与呼气峰值流速、哮喘症状、额外药物剂量或残疾指数的变化无关。在接受长期类固醇治疗的22名患者中，安慰剂或药物治疗四周期间的类固醇剂量没有差异，但在为期八周的开放试验期间显著降低（P<0.05）。我们得出结论，色甘酸钠给药对这组哮喘患者有治疗作用。
